Expertise in
5
conditions

Alessandro Comandone

Turin, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
Turin, IT 

Overview

Alessandro Comandone practices in Turin, Italy. Mr. Comandone is highly rated in 5 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Osteosarcoma, Desmoplastic Small Round Cell Tumor, Bone Tumor, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 55 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Turin, Italy
Other Locations
San Giovanni Suergiu, Italy
Gruppo, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized Phase II Trial Comparing the Activity of trabectedIn vs Gemcitabine in Patients With Metastatic or Locally Advanced Leiomyosarcoma Pretreated With Conventional Chemotherapy
A Randomized Phase II Trial Comparing the Activity of trabectedIn vs Gemcitabine in Patients With Metastatic or Locally Advanced Leiomyosarcoma Pretreated With Conventional Chemotherapy
Enrollment Status: Recruiting
Publish Date: January 02, 2026
Intervention Type: Drug
Study Drugs: Trabectedin, Gemcitabine
Study Phase: Phase 2
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Enrollment Status: Completed
Publish Date: December 04, 2024
Intervention Type: Drug
Study Drugs: Trabectedin, Olaparib
Study Phase: Phase 2
ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2)
ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2)
Enrollment Status: Completed
Publish Date: May 20, 2024
Intervention Type: Other, Drug
Study Drug: Mifamurtide
Study Phase: Phase 2
Follow-up in Low Risk Gastrointestinal Stromal Tumors (GISTs) - Retrospective Analysis of Clinical Features and Outcomes
Follow-up in Low Risk Gastrointestinal Stromal Tumors (GISTs) - Retrospective Analysis of Clinical Features and Outcomes
Enrollment Status: Completed
Publish Date: February 01, 2024
Intervention Type: Other
Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma.
Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma.
Enrollment Status: Completed
Publish Date: September 19, 2022
Intervention Type: Drug
Study Drugs: Standard Treatment (as per Protocol ISG SSG III), Intensified Chemotherapy
Study Phase: Phase 3
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
Enrollment Status: Completed
Publish Date: November 01, 2021
Intervention Type: Drug
Study Phase: Phase 2
Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma
Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Withdrawn
Publish Date: May 13, 2019
Intervention Type: Drug
Study Phase: Phase 3
Multicentric, Randomized Phase II Trial for the Treatment of Patients With Relapsed Osteosarcoma
Multicentric, Randomized Phase II Trial for the Treatment of Patients With Relapsed Osteosarcoma
Enrollment Status: Terminated
Publish Date: May 13, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

55 Total Publications

A consultation model integrating psychoanalysis and psychophysiology in oncology.
A consultation model integrating psychoanalysis and psychophysiology in oncology.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: January 14, 2025

Frequently Asked Questions about Alessandro Comandone

Is Alessandro Comandone a top-rated expert for Adult Soft Tissue Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Alessandro Comandone is classified as an Distinguished expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Alessandro Comandone participate in research or clinical trials?

Yes. Alessandro Comandone has published 55 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Alessandro Comandone's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Comandone's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile